AlphaRM, the analytical company, has provided a report on the pharmaceutical market dynamics for the year 2023.

The Pharmasyntez Group of Companies took bronze in the top 10 corporations in terms of growth in the retail commercial market in value terms, showing a 52% year-on-year growth compared to the year 2022.

The rapid growth and stable leading position in the company's ranking was achieved thanks to the antiviral drug Nomides.

In 2023, Nomides strengthened its leading market position, increasing its share from 38% to 42%. At the end of 10 months of 2023, more packs were sold than in the whole of 2022. According to AlphaRM data, Nomides has long surpassed the original drug Tamiflu in Russia and currently holds a 2-fold larger share.

As of today, Nomides is the only Oseltamivir on the Russian market, which is available in two dosage forms: powder for suspension in volumes of 10, 15 and 30 g and capsules in strength of 30, 45, and 75 mg.